An interventional study of Weekly 45 minute Sessions in Metastatic Cancer, Locally Advanced Cancer and Thoracic Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center — 13 open to participants now, 27 under way, 1 of them phase 3. Neoplasm Metastasis · Memorial Sloan Kettering Cancer Center.
Among the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center, this one is the 19th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2018, is one of 10 with no phase, reaches primary completion later than 4 of the 26 other live ones, and was the 41st registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →13 of the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 6–49
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 22+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 25 · Phase 3 3
First in 1998; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is close to the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 37 across the 50 interventional studies, 224 across the 6 observational. Of the 34 that completed or were terminated, 15 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
18 of the studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04143516Phase 3Memorial Sloan Kettering Cancer CenterTissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment | 2027-10 |
| NCT05117931Memorial Sloan Kettering Cancer CenterA Study of Amivantamab in People With Esophagogastric Cancer | 2026-11 |
| NCT01470105Memorial Sloan Kettering Cancer CenterImproving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases | 2026-11 |
| NCT03794635Memorial Sloan Kettering Cancer CenterAn Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer | 2026-12 |
| NCT02399995Memorial Sloan Kettering Cancer CenterHealth Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time | 2027-03 |
Add all 18 to your calendar (.ics) → With an account.
Among the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test an intervention to improve patients' and their caregivers' ability to manage difficult emotions and communicate about the patient's illness. There will be two versions of the intervention used for this study: a culturally tailored version for Latinx participants refined during Phase 1 of this study, and a version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. We will use the culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants. This culturally sensitive intervention has the potential to reduce Latino/a patient and caregiver distress and improve patient and caregiver quality of life, shared understanding of the patient's illness, and patients' and caregivers' ability to discuss, identify, and document patients' treatment preferences. The intervention is designed to minimize burden to patients, caregivers, and healthcare institutions to allow for easy integration into clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Patients:
For Caregivers:
Psychosocial expert eligibility requirements:
Exclusion Criteria:
For Patients
For Caregivers:
Patient-Caregiver Dyads:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Latino/a advanced cancer patients
Behavioral: Weekly 45 minute Sessions
Caregivers of Latino/a advanced cancer patients
Behavioral: Weekly 45 minute Sessions
The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study: 1. A culturally tailored version for Latinx participants refined during Phase 1 of this study (available in English and Spanish) 2. A version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. The culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants will be used. Interventions will occur weekly with a plus three-week window. Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention.
Feasibility of patient-caregiver communication-based intervention defined by participant enrollment
Time frame: 3 months
Feasibility of patient-caregiver communication-based intervention defined by participant retention
Time frame: 3 months
Plan to share: Undecided
Started Dec 2018 (actual). Primary completion is estimated for Dec 2026, 96 months after the start.
Of 295 non-industry interventional studies with no phase under Neoplasm Metastasis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 93. This study's planned 96 months is above that.
Counting every sponsor, half of 320 studies reached it within 54 months; a quarter within 28 and three quarters within 91.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →